RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:645388

Hemi-myelomeningocele

high confidenceSubtype of disorder

Also known as: Open split-cord malformation

Publications

9

21.1th percentile

Trials

0

Interventional, condition-specific

Researchers

40

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A very rare form of composite dysraphism characterized by the presence of a split cord and a myelomeningocele on one of the two hemicords. Hemicords can be in a single dural sac or in two separated dural sacs. Other spinal cord malformations can be associated. Due to the comparable prognosis it is considered as a subtype of myelomeningocele.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    9 matched papers (5 in last 10 years) Source

  3. Phenotype characterisedNot found

    No HPO disease–phenotype associations via Monarch for these Mondo IDs

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPartial

    None under the specific name; 32 for broader category myelomeningocele

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

9

9 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

9 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

5 in the last 10 years · high confidence · 21.1th percentile (publications denominator)

Phrase hits: 9 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

40

Distinct author names in 9 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Addas BM1 paper · 2014

    Division of Neurosurgery, Department of Surgery, Faculty of Medicine, King AbdulAziz University Hospital, PO Box 80215, Jeddah 21589, Kingdom of Saudi Arabia. Tel. +966 (12) 6401000 Ext. 18230. E-mail: bassamaddas@yahoo.com.

    Papers in Europe PMC
  2. 02
    Adel Al-Lami H1 paper · 2022

    Centre for Craniofacial and Regenerative Biology, King's College London, London, SE1 9RT, UK.

    Papers in Europe PMC
  3. 03
    Barrell WB1 paper · 2022

    Centre for Craniofacial and Regenerative Biology, King's College London, London, SE1 9RT, UK.

    Papers in Europe PMC
  4. 04
    de Saint-Denis T1 paper · 2025

    Pediatric Neuro-Orthopedic Department, Armand Trousseau Hospital, APHP Sorbonne University, Paris, France.

    Papers in Europe PMC
  5. 05
    Desale PS1 paper · 2025

    Department of Radiodiagnosis, Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra, India 44200.

    Papers in Europe PMC
  6. 06
    Dhombres F1 paper · 2025

    Fetal Medicine Department, Armand Trousseau Hospital, APHP Sorbonne University, GRC 26 and INSERM Limics, Paris, France. ferdinand.dhombres@aphp.fr.

    Papers in Europe PMC
  7. 07
    Gaur S1 paper · 2025

    Department of Radiodiagnosis, Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra, India 44200.

    Papers in Europe PMC
  8. 08
    Goos JAC1 paper · 2022

    Department of Plastic and Reconstructive Surgery and Hand Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands.

    Papers in Europe PMC
  9. 09
    Guci RD1 paper · 2026

    Department of Orthopedic and Traumatology, Faculty of Medicine, Universitas Sumatera Utara - Adam Malik General Hospital, Medan, North Sumatra, Indonesia.

    Papers in Europe PMC
  10. 10
    Gupta AK1 paper · 2016

    Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 32 trials are registered for myelomeningocele, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

high confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

32 interventional trials matched myelomeningocele, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: myelomeningocele

32

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Hemi-myelomeningocele — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Hemi-myelomeningocele" OR "Open split-cord malformation"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Hemi-myelomeningocele" OR "Open split-cord malformation"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"myelomeningocele"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T19:41:50.885Z